Pfizer licenses Scil's rhCD-RAP
US pharmaceutical giant Pfizer and German biopharmaceutical firm Scil Technology have signed a worldwide licensing deal to develop and commercialize the latter's candidate cartilage-specific growth factor, rhCD-RAP. The drug, a recombinant version of a naturally-occurring polypeptide involved in cartilage production, has been shown to stimulate cartilage synthesis in vitro in chondrocytes derived from patients suffering osteoarthritis.
The deal, which provides Pfizer with exclusive, worldwide rights to develop CD-RAP, entitles Martinsried-headquartered Scil to an upfront fee and milestone payments that could total $250.0 million. The agreement also stipulates that Scil receives royalties based on sales if the product is successfully brought to market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze